The research team, led by Jian Liu, Jin Bai, Cheng Deng, and Zukai Wu of the Third People’s Hospital of Xinjiang Uygur Autonomous Region and Union Hospital of Huazhong University of Science and Technology, set out to identify the mechanosensitive genes that behave abnormally in the vascular smooth muscle cells of patients with Marfan syndrome. These cells form the muscular middle layer of the aortic wall, and their behavior is exquisitely sensitive to the mechanical environment. When the extracellular matrix deteriorates, as it does in Marfan syndrome, the mechanical cues reaching these cells are distorted, and the cells respond with a maladaptive program of remodeling, proliferation, and inflammation that further weakens the vessel.

To find the molecular switches behind this response, the team re-analyzed publicly available transcriptomic data from the dataset GSE128101, comparing gene expression in aortic vascular smooth muscle cells derived from Marfan syndrome patients with those from healthy donors. The screen identified 436 differentially expressed genes. Functional enrichment analysis revealed that these genes clustered around several interconnected themes: extracellular matrix remodeling, mechanotransduction—the process by which cells convert mechanical stimuli into biochemical signals—inflammatory signaling, and cytoskeletal organization. In other words, the genetic signature of Marfan aortopathy is not simply a story of structural collapse, but of cells actively misreading their mechanical world.

Narrowing the field from hundreds of candidate genes to the most plausible mechanosensitive regulators required a layered computational strategy. The researchers applied protein-protein interaction analysis to map how the differentially expressed genes connect functionally, used pathway enrichment to highlight biological themes, and then employed a statistical feature-selection method known as minimum redundancy maximum relevance, which favors genes that are strongly associated with the disease while avoiding overlap with one another. The top-ranked candidate to emerge from this pipeline was TRPV4, a calcium-permeable ion channel well known in the mechanobiology literature for its role in translating stretch, pressure, and matrix stiffness into intracellular calcium signals. A second channel, TRPM5, was also identified as an overlapping candidate.

The team then moved from computation to the laboratory. Using quantitative reverse-transcription polymerase chain reaction on primary aortic medial smooth muscle cells isolated from Marfan syndrome patients and from organ donors, they confirmed that both TRPV4 and TRPM5 are expressed at significantly higher levels in the patient-derived cells. Immunofluorescence imaging added a further layer of evidence: in the Marfan-derived cells, TRPV4 showed enhanced localization at the cell membrane, the position from which the channel is best placed to sense mechanical forces and admit calcium. The patient cells also displayed elevated expression of inflammatory genes, suggesting that the channel’s overabundance coincides with an activated inflammatory state.

To test whether TRPV4 is merely a bystander or an active driver of this dysfunctional behavior, the researchers manipulated the channel’s expression in primary human aortic smooth muscle cells. When they overexpressed TRPV4, the cells became more proliferative, closed scratch wounds more rapidly in migration assays, and secreted higher levels of inflammatory cytokines. Critically, the overexpression also increased phosphorylation of components of the NF-κB pathway, a canonical inflammatory signaling cascade whose activation in the vessel wall is a recognized hallmark of aneurysm progression. When the researchers silenced TRPV4 using small interfering RNA, the opposite pattern emerged: proliferation slowed, wound closure diminished, cytokine secretion fell, and NF-κB phosphorylation decreased.

These results position TRPV4 as a leading mechanosensitive candidate associated with the vascular smooth muscle cell remodeling and inflammatory activation that characterize Marfan aortopathy. The finding fits within a broader and rapidly growing body of evidence implicating mechanosensitive ion channels in vascular disease. Recent studies have shown that deletion of endothelial TRPV4 protects the heart from pressure overload-induced hypertrophy, that deficiency of endothelial TRPV4 channels ameliorates experimental abdominal aortic aneurysm, and that the TRPV4-YAP axis mediates cytoskeletal and extracellular matrix remodeling in other tissues. TRPV4 has also been linked to vascular calcification and aortic stiffening, suggesting that the channel sits at a convergence point for multiple forms of arterial pathology.

The mechanistic logic of the new findings is compelling. In a healthy aorta, fibrillin-1-rich elastic fibers transmit mechanical load smoothly to smooth muscle cells, which maintain a quiescent, contractile phenotype. In Marfan syndrome, the fragmented matrix alters the pattern of force transmission, and the study suggests that TRPV4, abundant and membrane-enriched in the patient cells, converts this distorted mechanical input into pathological calcium entry. Calcium influx through TRPV4 would then activate downstream signaling, including NF-κB, driving the cells toward a synthetic, proliferative, and inflammatory state. This phenotypic switching of smooth muscle cells is widely regarded as a central event in aneurysm formation, and a channel that couples mechanical dysfunction to inflammatory activation is an attractive node for intervention.

The authors are careful to frame their conclusions as exploratory. The study relied on re-analysis of a public dataset with a limited number of samples, and although the qRT-PCR validation in primary patient cells strengthens the case, larger cohorts will be needed to confirm the consistency of the TRPV4 signature across the genetically and clinically heterogeneous Marfan population. The functional experiments were conducted in primary human aortic smooth muscle cells in vitro, which capture important aspects of the disease but cannot fully reproduce the complex mechanical and humoral environment of a living aneurysmal aorta. Direct mechanistic assays—for example, calcium imaging under controlled mechanical stimulation, or pharmacological blockade of TRPV4 in Marfan animal models—will be required to establish causality and to determine whether the channel is a viable biomarker or therapeutic target.

Even with those caveats, the study adds a significant piece to the mechanobiological puzzle of Marfan syndrome. Current clinical management of the Marfan aorta relies heavily on imaging surveillance, blood pressure control, and, in many cases, prophylactic surgical repair. Drugs such as beta-blockers and angiotensin receptor blockers slow but do not halt aortic dilation, and the search for molecular targets that address the underlying cellular dysfunction remains intense. If TRPV4’s role is confirmed in larger studies and disease models, the channel could offer a way to intervene at the point where mechanical failure is translated into cellular pathology—potentially allowing clinicians to quiet the inflammatory, remodeling program before the aorta reaches a dangerous diameter. In a condition where the difference between stability and catastrophe is measured in millimeters, a molecular handle on that translation would be a welcome advance.

Subject of Research: Mechanosensitive gene programs, particularly the TRPV4 calcium channel, in Marfan syndrome aortopathy

Article Title: TRPV4 is Associated with a Marfan Syndrome-Related Mechanosensitive Gene Program in Aortic Smooth Muscle Cells

Article References: TRPV4 is Associated with a Marfan Syndrome-Related Mechanosensitive Gene Program in Aortic Smooth Muscle Cells. (n.d.). https://doi.org/10.1007/s10528-026-11447-6

Image Credits: AI Generated

DOI: 10.1007/s10528-026-11447-6

Keywords: Marfan syndrome, TRPV4, mechanotransduction, vascular smooth muscle cells, aortic aneurysm, inflammation, NF-κB pathway, extracellular matrix remodeling, calcium channel, aortopathy, Biochemical Genetics, gene expression

Hypoxic pulmonary hypertension develops when the lungs are deprived of adequate oxygen over long periods, as occurs at high altitude or in chronic lung disease. The low-oxygen environment provokes an aggressive remodeling of the small pulmonary arteries: the muscular walls thicken, cells proliferate excessively, and the vessel lumens narrow, driving up resistance to blood flow. The right side of the heart, forced to pump against this rising resistance, experiences elevated pressure and eventually fails. Current treatments dilate vessels or target a handful of known signaling pathways, but they do not reverse the structural remodeling itself, which is why investigators continue to search for the molecular switches that govern it.

SCAMP3 belongs to a family of proteins embedded in the membranes of secretory carriers, the intracellular vesicles that shuttle material between cellular compartments. Although its day job involves membrane trafficking, SCAMP3 has recently attracted attention in cancer biology, where studies have linked it to the proliferation and migration of triple-negative breast cancer cells through modulation of AKT, ERK, and STAT3 signaling, and to tumor progression via a c-MYC–β-catenin–SQSTM1 axis. Elevated SCAMP3 expression has also been documented in pancreatic adenocarcinoma. What remained unknown was whether this trafficking protein plays any role in the vascular smooth muscle cells whose runaway growth defines pulmonary hypertension.

To find out, the team led by Peng Ye, Le Zhu, and corresponding authors Juan Zhang and Xiaomin Jiang turned to a well-established mouse model. Fifty mice were randomly divided into five groups of ten: a blank control group, a group exposed to hypoxia to induce pulmonary hypertension, a group receiving a non-targeting small interfering RNA as a negative control, a group treated with siRNA against SCAMP3, and a combined group receiving siRNA against both SCAMP3 and WWP1. The researchers then measured right ventricular systolic pressure, the Fulton index—the ratio of right ventricle weight to left ventricle plus septum weight, a standard gauge of right heart hypertrophy—and pulmonary function, while hematoxylin-eosin staining revealed the architecture of the pulmonary vessels.

The results were striking. Compared with normoxic animals, mice in the hypoxia group showed significantly increased SCAMP3 expression, both at the message and protein levels, alongside the expected rises in right ventricular systolic pressure and Fulton index and clear signs of vascular remodeling. In parallel experiments on human pulmonary artery smooth muscle cells grown under low-oxygen conditions, hypoxia again raised SCAMP3 protein and increased cell proliferation as measured by OD450 values in proliferation assays, while apoptosis rates fell and WWP1 protein levels dropped. In other words, the hypoxic environment simultaneously boosted the pro-growth trafficking protein and suppressed the ubiquitin ligase that would normally restrain growth.

Silencing SCAMP3 reversed this picture. In the hypoxia plus si-SCAMP3 group, SCAMP3 expression fell, proliferation of the pulmonary artery smooth muscle cells declined, and apoptosis rose significantly, with WWP1 protein expression climbing in step. In the living animals, knocking down SCAMP3 eased the hemodynamic and structural consequences of hypoxia: right ventricular systolic pressure and the Fulton index dropped, and the remodeling indexes calculated from stained vessel sections improved. The findings suggest that SCAMP3 acts as a brake release on the abnormal growth of vascular smooth muscle cells, and that removing it restores a healthier balance between cell division and cell death in the remodeled pulmonary arteries.

The mechanistic twist came from the double-knockdown group. When the researchers silenced WWP1 alongside SCAMP3, the benefits of SCAMP3 knockdown were partially undone: SCAMP3 expression crept back up, proliferation resumed, apoptosis declined, and WWP1 protein fell. This partial rescue implies that WWP1 sits downstream of SCAMP3 in the pathway, and that the protective effect of removing SCAMP3 depends at least in part on allowing WWP1 to accumulate. WWP1, a WW domain-containing E3 ubiquitin ligase, is known to tag other proteins for degradation and to regulate signaling cascades such as transforming growth factor-beta, and it has previously been implicated in cardiac hypertrophy, where targeting WWP1 prevented pathological heart muscle growth by destabilizing DVL2 through inhibition of K27-linked ubiquitination.

The statistical rigor of the study lends weight to its conclusions. All comparisons between the hypoxia group and the normoxia group, between the hypoxia plus si-SCAMP3 group and the hypoxia group, and between the double-knockdown group and the single SCAMP3 knockdown group reached significance at P less than 0.05. The animal work was approved by the Institutional Animal Care and Use Committee of Nanjing First Hospital and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, with efforts made to minimize animal suffering. The study was funded by the National Natural Science Foundation of China and the Nanjing Health Science and Technology Development Special Fund Project, and the authors declared no conflicts of interest.

For the field, the study adds SCAMP3 to a growing roster of trafficking and ubiquitination proteins implicated in pulmonary vascular disease, a list that includes recent work on ErbB3 in endothelial dysfunction, BRCC3 regulation of ALK2 in vascular smooth muscle, and endothelial fIS1 deSUMOylation. What distinguishes the new findings is the proposed SCAMP3–WWP1 axis, which links membrane trafficking to the ubiquitin-proteasome machinery that decides the fate of growth-regulating proteins. If future work confirms the interaction at the molecular level—for example by identifying which substrates WWP1 tags when SCAMP3 is depleted—the pathway could yield drug targets capable of not just dilating vessels but reversing the wall thickening that makes pulmonary hypertension so lethal.

The caveats are real. The double knockdown only partially restored the disease phenotype, suggesting that other pathways downstream of SCAMP3 remain to be discovered, and the experiments were confined to mice and cultured cells rather than human tissue. The authors note that all original data are available upon reasonable request, which should help other laboratories test the mechanism independently. Still, the core message is clear and potentially consequential: a protein once regarded as a mundane component of the cellular shipping system appears to help orchestrate the vascular remodeling that underlies hypoxic pulmonary hypertension, and dialing it down—perhaps through RNA-based therapeutics or small molecules that stabilize WWP1—may one day offer patients a way to halt, or even reverse, the structural damage that current drugs cannot touch.

Subject of Research: The role of SCAMP3 knockdown and the E3 ubiquitin ligase WWP1 in attenuating hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Article Title: Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1

Article References: Secretory Carrier Membrane Protein 3 Knockdown Attenuates Hypoxic Pulmonary Hypertension Potentially Involving WW Domain-Containing E3 Ubiquitin Protein Ligase 1. (n.d.). https://doi.org/10.1007/s10528-026-11446-7

Image Credits: AI Generated

DOI: 10.1007/s10528-026-11446-7

Keywords: SCAMP3, WWP1, hypoxic pulmonary hypertension, pulmonary vascular remodeling, pulmonary artery smooth muscle cells, E3 ubiquitin ligase, apoptosis, cell proliferation, right ventricular systolic pressure, Fulton index, hypoxia, Biochemical Genetics